Annual report pursuant to Section 13 and 15(d)

Note 18 - Agreements (Details Textual)

v3.20.1
Note 18 - Agreements (Details Textual)
 1 Months Ended 12 Months Ended
Jul. 31, 2014
USD ($)
Dec. 31, 2011
USD ($)
Nov. 30, 2009
Jan. 31, 2002
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Research and Development Expense, Total         $ 5,338,267 $ 4,221,881
Reliable Supply Agreement [Member]            
Long-term Contract for Supplies, Option to Extend, Term     3 years      
Tc99m Tilmanocept License Agreement [Member]            
License Issue Fee       $ 25,000    
License Maintenance Fee       25,000    
Minimum Annual Royalty       $ 25,000    
Expanded Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | Cost of Sales [Member] | License [Member]            
Cost of Goods and Services Sold, Total         2,000 1,000
Amended and Restated Tilmanocept License Agreement [Member]            
Research and Development Expense, Total         191,000 35,000
Tilmanocept License Agreement [Member]            
License Issue Fee $ 25,000          
License Maintenance Fee 25,000          
Minimum Annual Royalty $ 25,000          
Research and Development Expense, Total         355,000 250,000
Astra Zeneca Agreement [Member]            
Milestone Payments, Maximum, Cash, Clinical Development and Regulatory Filing Milestones   $ 6,500,000        
Milestone Payments, Maximum, Cash, Due Following Receipt of Regulatory Approvals and Initiation of Commercial Sales   11,000,000        
Astra Zeneca Agreement [Member] | License [Member]            
Cost of Goods and Services Sold, Total   $ 5,000,000        
Alseres Pharmaceuticals Agreement [Member]            
Research and Development Expense, Total         $ 0 $ 0
Ratio of Entitled Salary         4  
Employment Agreement [Member] | Maximum [Member]            
Loss Contingency, Estimate of Possible Loss         $ 2,000,000